Boyds’ chief development officer, Dr Nick Meyers, and director of regulatory affairs, Dr Eric Hardter, provide advice and guidance to drug developers and sponsors on de-risking the Investigational New Drug (IND) process.
Shutterstock
De-risking the Investigational New Drug (IND) process
Boyds’ chief development officer, Dr Nick Meyers, and director of regulatory affairs, Dr Eric Hardter, provide advice and guidance to drug developers and sponsors on de-risking the Investigational New Drug (IND) process.
Published:
|
4 min read
Last updated:
Sign up to our newsletter
The week's biggest stories from this industry, direct to your inbox.